N-(5-Bromo-3-methyl-2-pyridinyl)-N-methylbenzamide

‌Ozenoxacin Intermediate (CAS 446299-80-5) | High-Performance API Synthesis Material‌
‌Google Search Keywords‌: Ozenoxacin Intermediate, CAS 446299-80-5, Antibacterial API Intermediate, Quinolone Synthesis Material, Pharmaceutical Intermediate

🔬 ‌Product Overview‌
Ozenoxacin Intermediate (CAS 446299-80-5) is a critical building block in the synthesis of ‌Ozenoxacin‌, a non-fluorinated quinolone antibiotic used to treat bacterial skin infections like impetigo. This intermediate ensures high-yield, scalable production of Ozenoxacin API while meeting stringent pharmaceutical quality requirements.
‌Primary Function‌: Facilitates efficient and precise API synthesis for antibacterial drugs.
‌Applications‌: Antibiotic manufacturing, topical drug formulations, veterinary medicine.

✅ ‌Key Advantages‌
⭐ ‌Ultra-High Purity‌

• Purity ≥99.5% (HPLC/LC-MS verified), minimizing by-products and ensuring batch consistency.

⚙️ ‌Process Efficiency‌

• Optimizes synthesis pathways, reducing production steps by 20-25% compared to traditional methods.

🌡️ ‌Thermal Stability‌

• Stable at room temperature (15-25°C), ideal for long-term storage and transport.

📜 ‌Regulatory Ready‌

• Compliant with ‌ICH Q11‌ and ‌USP/EP‌ standards for pharmaceutical intermediates.

📋 ‌Applications‌

1. ‌API Production‌: Core component in Ozenoxacin API batch manufacturing.

2. ‌Topical Antibacterials‌: Supports formulation of creams/ointments for skin infections.

3. ‌Veterinary Medicine‌: Used in antibacterial solutions for animal healthcare.

4. ‌Research & Development‌: Key material for novel quinolone derivative studies.

🏅 ‌Quality Certifications‌

• Rigorous testing via ‌HPLC, GC, NMR, and Mass Spectrometry‌ (aligned with USP/EP/ICH guidelines).

• Batch-specific Certificate of Analysis (CoA) with full traceability and impurity profiles.

🌐 ‌Market Trends‌
The global antibacterial API market is projected to grow at ‌5.8% CAGR (2024-2030)‌, driven by rising demand for topical antibiotics and drug-resistant infection treatments. Ozenoxacin intermediates are pivotal in addressing unmet needs for non-fluorinated quinolone therapies.

🔍 ‌Why Choose Us?‌

• ‌Bulk Supply‌: Scalable production with flexible batch sizes (grams to kilograms).

• ‌Custom Synthesis‌: Tailored purity grades and analytical support for R&D.

• ‌Global Compliance‌: Shipped with SDS and regulatory documentation for seamless integration.